Nasus Pharma Market Risk Adjusted Performance
| NSRX Stock | | | 2.49 -0.01 -0.40% |
The Market Risk Adjusted Performance signal for Nasus Pharma reflects patterns observed in trading data. Availability can differ across markets, exchanges, and instruments. Nasus Pharma has a market cap of 29.28 M.
Correlation Analysis can help frame allocation decisions. Adding Nasus Pharma to a portfolio enables side-by-side comparison with other holdings. This view summarizes available data without implying outcomes. Broader economic conditions can influence Nasus Pharma's company valuation — related indicators include
signals in real.
Our
How to Trade Nasus Pharma guide. The guide covers key considerations relevant to Nasus Stock order placement. It provides context that complements the data on this page for Nasus Pharma.
Nasus Pharma has current Market Risk Adjusted Performance of 5.07.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | 5.07 | |
| ER[a] | = | Expected return on investing in Nasus Pharma |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Market Risk Adjusted Performance Peers Comparison
Market Risk Adjusted Performance Relative To Other Indicators
Nasus Pharma ranks first in market risk adjusted performance among leading competitors. It is currently under evaluation in maximum drawdown among leading competitors reporting about
11.24 of Maximum Drawdown per Market Risk Adjusted Performance. At
11.24 , Nasus Pharma's Maximum Drawdown-to-Market Risk Adjusted Performance multiple reflects the spread between these metrics
Other Technical Indicators